1293P KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in combination with platinum doublet chemotherapy as first-line (1L) treatment in patients with advanced NSCLC harboring resistant oncogenic driver alterations

W Fang,Y Yang,Y Huang,X Li,S Huang,J Wu,Y Li,B Chang,S Hu,S Yang,J Xu,H Van,L Zhi,Y Xia,L Li,F Yang,T Xu,L Zhang

doi:10.1016/j.annonc.2021.08.1895

1293P KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in combination with platinum doublet chemotherapy as first-line (1L) treatment in patients with advanced NSCLC harboring resistant oncogenic driver alterations

W Fang, Y Yang + Show 16 more

Open Access

https://doi.org/10.1016/j.annonc.2021.08.1895

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2021
Citations: 3	License type: publisher-specific-oa

Affiliation: Sun Yat-sen University Cancer Center, First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Xiamen University, First Affiliated Hospital of Henan University of Science and Technology, Hubei Cancer Hospital, Zhengzhou Central Hospital, Jiangsu T-mab BioPharma (China)

#Platinum Doublet Chemotherapy #NSCLC Pts + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

KN046 (a novel bispecific antibody that bifunctionally targets CTLA4 and PD-L1) in combination with platinum doublet chemotherapy as 1L therapy showed promising efficacy and acceptable safety in stage IV NSCLC patients. Here, we report results from a cohort of systemic therapy naive NSCLC pts with resistant oncogenic driver alterations.

Full Text